How to Maintain "After Losing Weight"—The Future of Obesity Treatment Reconsidered by Daily GLP-1 Medication

Losing weight is difficult. However, in the medical field, there is an even more challenging issue: how to maintain the weight once it has been lost.

In recent years, GLP-1 injectable drugs have significantly transformed the world of obesity treatment. These drugs, such as semaglutide and tirzepatide, have gained global attention for their ability to suppress appetite, prolong satiety, and affect blood sugar and metabolism. Many people might be familiar with brand names like Wegovy, Ozempic, Mounjaro, and Zepbound.

However, these drugs face a significant practical challenge: weight tends to return once the injections are stopped.

A new study reported by the BBC and others suggests that a daily oral medication could be an effective option for addressing the issue of "post-weight loss maintenance." The drug in question is orforglipron, developed by Eli Lilly, and approved in the U.S. under the name Foundayo as an oral GLP-1 receptor agonist.

The study involved 376 American adults who had already used GLP-1 injectable drugs for over 72 weeks and lost weight. After stopping the injections, participants took orforglipron or a placebo daily for a year, without knowing whether they were taking the real drug or a placebo.

The results were clear. Those who had used tirzepatide maintained about 75% of their weight loss by switching to orforglipron, compared to about 49% in the placebo group. For those who switched from semaglutide, the orforglipron group maintained about 79% of their weight loss, while the placebo group maintained only about 38%.

In other words, a route has emerged where, instead of doing nothing after stopping injections, maintenance can be achieved with oral medication.

The Next Challenge Born from the Success of Injectable Drugs

GLP-1 injectable drugs have been called "game-changers" in obesity treatment. They have become a powerful option for those who did not achieve sufficient results with traditional diet and exercise therapy alone.

However, even if weight is lost with medication, obesity itself does not become a short-term issue. Many experts have come to view obesity as a "chronic and relapsing disease." Like hypertension and diabetes, it often requires long-term management rather than just a fixed period of treatment.

Here, the issue becomes the ongoing burden on patients: weekly injections, refrigerated storage, travel portability, costs, psychological resistance, and fear of needles. Even if medically effective, many people find it difficult to continue in their daily lives.

The reason this study is noteworthy is that it suggests oral medication could be used as "maintenance therapy after weight loss." The initial significant weight loss is achieved with injectable drugs, and then maintained with oral medication. If this flow can be safely and effectively established, obesity treatment may become more realistic and easier to continue.

What is Orforglipron?

Orforglipron is a type of GLP-1 receptor agonist. GLP-1 is a hormone in the body that is secreted after eating, promoting insulin secretion, slowing gastric movement, and enhancing satiety. GLP-1 drugs utilize this function to suppress appetite and calorie intake.

Traditional GLP-1 drugs have often been in injectable form. However, orforglipron is a small molecule oral medication taken daily, offering a significant appeal to those who wish to avoid injections. In the U.S., it is approved as an oral GLP-1 drug that can be taken without dietary or fluid intake restrictions.

Compared to injections, oral medication has a lower psychological barrier. Taking medication is something many people already do routinely. For those who take daily medication for diabetes, hypertension, or dyslipidemia, it may be more acceptable than injections.

However, being an oral medication does not make it a panacea. Side effects were reported in this study as well, mostly mild to moderate gastrointestinal symptoms such as nausea, constipation, vomiting, and diarrhea, which are common with GLP-1 drugs.

Moreover, the study period was one year. Will the weight maintenance effect continue for two years, five years, or ten years? Are there any long-term safety concerns? Which patients is it suitable for, and which is it not? These questions require further investigation.

"Rebound" is Not a Lack of Willpower

This study is socially significant because it also influences how obesity and rebound are perceived.

Previously, weight regain was often seen as a "lack of effort" on the part of the individual. However, weight regulation involves various factors such as appetite, hormones, metabolism, brain reward systems, living environment, stress, sleep, income, and work style.

When weight drops rapidly, the body tries to prepare for an energy shortage. Appetite increases, energy expenditure decreases, and physiological reactions occur to return to previous weight. This is not a problem that can be solved with mere determination or willpower.

Therefore, the idea of supporting post-weight loss maintenance with medication shifts obesity treatment from a "temporary diet" to "chronic disease management."

However, this perspective is also debated. While treating obesity as a disease broadens access to treatment, there are concerns about becoming a society overly dependent on medication, excessive marketing by pharmaceutical companies, and strengthening stigma around body shape.

Mixed Expectations and Cautions on Social Media

On social media and online forums, there is both excitement and apprehension about oral GLP-1 drugs.

The most common reaction is the welcome of transitioning from injections to oral medication. For those who are needle-averse, find injections burdensome in daily life, or struggle with storage and transport during travel or business trips, oral medication appears very attractive. On Reddit's GLP-1-related communities, there are posts welcoming the introduction of orforglipron as "increasing options."

Conversely, there is also debate about "which is truly more convenient." Some argue that a weekly injection is, in a sense, easier than taking daily medication. Daily medication can lead to forgetting doses. For those without resistance to injections, a treatment that requires only a weekly commitment may be easier to incorporate into their lives.

There is also noticeable dissatisfaction with the price. In the U.S., the out-of-pocket cost for orforglipron starts at $149 per month for a low dose, but even this is not a small burden when considering long-term use. On social media, there is criticism of pharmaceutical companies, suggesting that drug prices are set based on "what people can pay" rather than manufacturing costs.

Furthermore, there is a strong distrust of the advertising and marketing of GLP-1 drugs overall. One user expressed concern that, despite GLP-1 drugs being aids to enable dietary and lifestyle improvements rather than magical weight loss solutions, advertisements might lead to misunderstandings that one can "lose weight quickly and maintain it even after stopping."

There are also concerns about side effects. While gastrointestinal symptoms like nausea and constipation are well-known, the story changes with long-term use. Especially as obesity treatment enters the "maintenance" phase, questions about how long to continue the medication become unavoidable. Can it be stopped after a year? Should it be continued for several years? Or, like hypertension medication, will it need to be taken semi-permanently?

When breaking down the reactions on social media, the following structure emerges:

Firstly, practical welcome as "good news for those who dislike injections."
Secondly, the expectation for "wider adoption if it becomes cheaper" in terms of access.
Thirdly, cultural anxiety about "becoming a society too reliant on medication."
Fourthly, medical expectation that "if rebound can be prevented, the common understanding of obesity treatment will change."
Fifthly, cautious opinions that "long-term safety and costs are still unclear."

In other words, the atmosphere on social media is not one of simple praise. Rather, it indicates that obesity treatment drugs are already deeply intertwined with societal values, healthcare costs, body image, and pharmaceutical business issues.

Is Oral Medication a "Substitute for Injections" or a "Bridge for Maintenance"?

A key point in the debate over orforglipron is how to position this drug.

One perspective is that it is a substitute for injectable drugs. People who do not want injections use oral medication from the start. This lowers the barrier to starting treatment. It is particularly meaningful for those with a fear of needles or those who find the storage and delivery of injectable drugs inconvenient.

Another perspective is that it serves as "maintenance therapy" after injectable drugs. Initially, significant weight loss is achieved with potent injectable drugs, and then weight regain is suppressed with oral medication. This study strongly suggests this possibility.

This concept is also important from a healthcare economics standpoint. Injectable drugs are expensive and pose a significant burden on insurance systems and public healthcare. If oral medications can be manufactured and provided more cheaply, they may become easier to use as long-term maintenance therapy.

However, manufacturing cheaply and actually delivering it cheaply to patients are separate issues. As dissatisfaction with prices on social media indicates, depending on drug pricing and insurance coverage systems, even oral medications may not be accessible to everyone.

Obesity is deeply connected with income, food environment, work environment, education, and regional disparities. If only those who can use the advanced drugs can maintain health, healthcare disparities may actually widen.

The Significance of the Drug as a "Health Risk Reducer"

This study reports that not only weight but also indicators such as blood pressure, lipids, and blood sugar were maintained. This is significant.

The goal of obesity treatment is not just the numbers on the scale. It is to reduce health risks associated with obesity, such as type 2 diabetes, cardiovascular disease, sleep apnea, fatty liver, and joint burden.

If maintaining weight also preserves improvements in blood sugar, blood pressure, and lipids, it may be possible to reduce other medications in the long term. For example, for patients taking multiple medications for hypertension, dyslipidemia, and diabetes, intervening in obesity itself may reduce the overall treatment burden.

Of course, this needs to be viewed cautiously. Maintaining weight and actually reducing major events like heart attacks or strokes are not the same. Further large-scale and long-term studies are needed for such long-term outcomes.

However, the perspective that weight maintenance is not merely for aesthetic purposes but is related to the prevention and management of chronic diseases will likely grow stronger in the future.

The Question of "Will I Have to Take It for Life?"

When a new drug emerges, expectations inevitably rise. However, the biggest question posed by this study is actually very mundane and weighty.

How long will it be necessary to continue taking this medication?

Is one year of use sufficient? Will the body adapt to the new weight if continued for several years? Or, if the medication is stopped, will there be a high risk of weight returning, ultimately requiring long-term use?

Among experts, the view that obesity should be managed chronically is spreading. If so, GLP-1 drugs will be treated not as "short-term diet drugs" but as "long-term treatment drugs."

If this point is left ambiguous and the drug spreads rapidly, patients will begin treatment with insufficient information. Before starting, it is necessary to thoroughly discuss with healthcare providers not only the effects but also what happens after stopping, costs, side effects, relationships with pregnancy and other diseases, and combinations with lifestyle improvements.

It's Not Irrelevant for Japan Either

While this report mainly focuses on the U.S. and the U.K., it is not irrelevant for Japan.

In Japan, obesity, diabetes, dyslipidemia, and hypertension are also important medical issues. At the same time, there is strong social pressure regarding body shape and weight loss, raising the possibility of misuse for cosmetic purposes and inappropriate online prescriptions.

GLP-1 drugs should ideally be used under the diagnosis and management of a physician. They have side effects and contraindications and precautions. If they spread merely as "drugs that make you lose weight just by taking them," it could lead to health damage and misuse.

Especially with oral medications, the psychological barrier is lower than with injections. This is an advantage but also a risk of widespread casual use. The more they become a topic on social media, the more likely medical information, advertisements, experiences, and misinformation will mix.

Therefore, when drugs like orforglipron emerge, it is necessary to carefully convey not only the magnitude of the effect but also who needs it and who does not.

Obesity Treatment Shifts from "Weight Loss Competition" to "Maintenance Medicine"

This study indicates that the focus of obesity treatment is shifting.

Until now, the emphasis has been on "how much weight can be lost." How many percent have you lost? How many kilograms have you reduced? Which is stronger, injectable or oral medication? Certainly, these are important indicators.

However, what truly matters to patients is whether they can maintain that state healthily. If weight drops but returns the moment the medication is stopped, the treatment is not complete. Conversely, even if there is no significant weight loss, if blood pressure and blood sugar improve, quality of life rises, and it can be continued for a long time, its value is significant.

The research on orforglipron expands the idea from drugs that "lose" weight to drugs that "protect" the weight lost.

Of course, conclusions should not be rushed at this point. The study was funded by a pharmaceutical company, involved 376 participants, and lasted one year. There was no direct comparison with groups that continued injections, and long-term safety, cost-effectiveness, and adherence in real-world settings remain future challenges.

Nevertheless, the direction indicated by this study is significant. Obesity treatment is entering a stage where it considers not only short-term weight loss success but also subsequent maintenance, ease of integration into life, healthcare costs, and patient options.

It is natural for expectations and concerns to be mixed on social media. This is not just news about a new drug. It connects to larger themes about how we understand obesity, manage weight, and consider the boundaries between healthcare and life.

Will oral medication replace injections? Will it establish itself as maintenance therapy after injections? Or will it remain an option only for some due to cost and safety issues?

The answer is not yet clear. But at least, the next focus of obesity treatment is undoubtedly shifting from "how to lose weight" to "how not to regain it."